Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228513 | 1.00 | SORD (0.51) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| SCHEMBL2320496 | 1.00 | SORD (0.51) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| SCHEMBL30785422 | 0.98 | SORD (0.50) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| SCHEMBL2320514 | 0.98 | SORD (0.50) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| SCHEMBL468382 | 0.98 | SORD (0.50) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| Thiophene SCHEMBL26658665 | 0.86 | L3MBTL1 (0.44) | SORDKDM4ELMNAL3MBTL1SLC6A7 | |
| SCHEMBL25378983 | 0.83 | CHRNB2 (0.55) | KDM4EHTR1AALDH1A1 | |
| SCHEMBL19035674 | 0.83 | HRH4 (0.50) | SORDKDM4ELMNAL3MBTL1HTR1A | |
| SCHEMBL30306065 | 0.83 | CHRNB2 (0.55) | KDM4EHTR1AALDH1A1 | |
| SCHEMBL5024 | 0.83 | SORD (0.49) | SORDKDM4ELMNAL3MBTL1SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | claimed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | claimed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | SORD 4104/4885KDM4E 872/4885LMNA 3137/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | SORD 4104/4885KDM4E 872/4885LMNA 3137/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | SORD 4104/4885KDM4E 872/4885LMNA 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.